Reduced prevalence of SARS-CoV-2 infection in ABO blood group O

Autor: Keld Homburg, Bitten Aagaard, Henrik Støvring, Kjell Titlestad, Morten Bagge Hansen, Torben Barington, Thure Mors Haunstrup, Mike Bogetofte Barnkob, Rune B. Larsen, Bjarne Kuno Møller, Anton Pottegård

Publikováno v: Barnkob, M B, Pottegård, A, Støvring, H, Haunstrup, T M, Homburg, K, Larsen, R, Hansen, M B, Titlestad, K, Aagaard, B, Møller, B K & Barington, T 2020, ' Reduced prevalence of SARS-CoV-2 infection in ABO blood group O ', Blood Advances, vol. 4, no. 20, pp. 4990-4993 . https://doi.org/10.1182/BLOODADVANCES.2020002657
Barnkob, M B, Pottegård, A, Støvring, H, Haunstrup, T M, Homburg, K, Larsen, R, Hansen, M B, Titlestad, K, Aagaard, B, Møller, B K & Barington, T 2020, ' Reduced prevalence of SARS-CoV-2 infection in ABO blood group O ', Blood advances, vol. 4, no. 20, pp. 4990-4993 . https://doi.org/10.1182/bloodadvances.2020002657
Blood Adv
Barnkob, M B, Pottegård, A, Støvring, H, Haunstrup, T M, Homburg, K, Larsen, R, Hansen, M B, Titlestad, K, Aagaard, B, Møller, B K & Barington, T 2020, ' Reduced prevalence of SARS-CoV-2 infection in ABO blood group O ', Blood advances, vol. 4, no. 20, pp. 4990–4993 . https://doi.org/10.1182/bloodadvances.2020002657

Identification of risk factors for contracting and developing serious illness following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of paramount interest. Here, we performed a retrospective cohort analysis of all Da

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3628c42af94737871026b6ddd28b3df7
https://pure.au.dk/portal/da/publications/reduced-prevalence-of-sarscov2-infection-in-abo-blood-group-o(3ff85e08-215c-4d68-8d0b-18fb8963aa0b).html

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial

Autor: Stephan Windecker, Stefano Barco, Ulrike Held, Tim Sebastian, François Mach, Giuseppe Colucci, Marc Philip Righini, Nils Kucher, Thomas Rosemann, Roland Bingisser, Andre Frenk, Rebecca Spescha, Lucia Mazzolai, Stefan Stortecky, Bernhard Gerber

Publikováno v: Barco, Stefano; Bingisser, Roland; Colucci, Giuseppe; Frenk, André; Gerber, Bernhard; Held, Ulrike; Mach, Francois; Mazzolai, Lucia; Righini, Marc; Rosemann, Thomas; Sebastian, Tim; Spescha, Rebecca; Stortecky, Stefan; Windecker, Stephan; Kucher, Nils (2020). Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Trials, 21(1), p. 770. BioMed Central 10.1186/s13063-020-04678-4
Trials, vol. 21, no. 1, pp. 770
Trials, Vol 21, Iss 1, Pp 1-3 (2020)
Trials

Objectives The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ad9a582d1159038210e15d6d804a5e7

The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

Autor: Jakob Stensballe, Klaus T. Kristiansen, Peter Søe-Jensen, Morten H. Bestle, Pär I. Johansson, Niels Erikstrup Clausen, Anders Perner

Publikováno v: Trials, Vol 21, Iss 1, Pp 1-2 (2020)
Trials
Johansson, P I, Bestle, M, Søe-Jensen, P, Kristiansen, K T, Stensballe, J, Clausen, N E & Perner, A 2020, ' The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19 : A structured summary of a study protocol for a randomized controlled trial ', Trials, vol. 21, 746 . https://doi.org/10.1186/s13063-020-04696-2

Objectives To investigate the effect of continuous infusion of the potential endothelial cytoprotective agent prostacyclin (Iloprost) 1 ng/kg/min vs. placebo for 72 hours on pulmonary endotheliopathy in mechanically ventilated COVID-19 patients. Tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4a22b49d5e0c1495eb7e867dde5ed86
http://link.springer.com/article/10.1186/s13063-020-04696-2

[Isolation of Francois-Heglin syndrome; biological reactions of atypical pneumonias: cold agglutinins, syphilis blood tests and Hirst reaction].

Autor: TURIAF J, BLANCHON, EYQUEM, CHABOT

Publikováno v: Journal francais de medecine et chirurgie thoraciques [J Fr Med Chir Thorac] 1952; Vol. 6 (2), pp. 169-78.